Free Trial

Callan Capital LLC Invests $735,000 in Takeda Pharmaceutical Co. (NYSE:TAK)

Takeda Pharmaceutical logo with Medical background

Callan Capital LLC acquired a new position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 49,425 shares of the company's stock, valued at approximately $735,000.

Several other institutional investors have also recently modified their holdings of TAK. First Trust Advisors LP increased its position in Takeda Pharmaceutical by 2.0% during the fourth quarter. First Trust Advisors LP now owns 3,240,932 shares of the company's stock worth $42,910,000 after buying an additional 62,718 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Takeda Pharmaceutical by 14.6% during the fourth quarter. Northern Trust Corp now owns 1,873,588 shares of the company's stock valued at $24,806,000 after acquiring an additional 238,161 shares during the last quarter. Soleus Capital Management L.P. increased its position in Takeda Pharmaceutical by 136.0% during the 4th quarter. Soleus Capital Management L.P. now owns 1,180,000 shares of the company's stock worth $15,623,000 after purchasing an additional 680,000 shares in the last quarter. Summit Global Investments increased its position in Takeda Pharmaceutical by 75.5% during the 4th quarter. Summit Global Investments now owns 729,200 shares of the company's stock worth $9,655,000 after purchasing an additional 313,642 shares in the last quarter. Finally, Toronto Dominion Bank acquired a new position in Takeda Pharmaceutical in the 4th quarter valued at about $6,760,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Trading Up 0.8%

Shares of TAK traded up $0.12 on Wednesday, hitting $15.14. 1,629,468 shares of the stock traded hands, compared to its average volume of 1,992,140. Takeda Pharmaceutical Co. has a 1 year low of $12.80 and a 1 year high of $16.00. The stock's 50 day moving average is $14.86 and its two-hundred day moving average is $14.35. The firm has a market capitalization of $48.17 billion, a P/E ratio of 9.51 and a beta of 0.23. The company has a quick ratio of 0.52, a current ratio of 1.01 and a debt-to-equity ratio of 0.57.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The business had revenue of $7.34 billion for the quarter, compared to analysts' expectations of $8.02 billion. Takeda Pharmaceutical had a return on equity of 10.64% and a net margin of 2.36%. As a group, sell-side analysts predict that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Check Out Our Latest Report on TAK

About Takeda Pharmaceutical

(Free Report)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Read More

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Should You Invest $1,000 in Takeda Pharmaceutical Right Now?

Before you consider Takeda Pharmaceutical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.

While Takeda Pharmaceutical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines